News and Trends 28 Oct 2022
Rila Therapeutics exits stealth mode to address renal fibrosis
Rila Therapeutics, a biotherapeutics company focused on addressing the critical unmet medical needs to treat renal fibrosis, has emerged from stealth mode. Rila Therapeutics has identified a promising, first-in-class allosteric small molecule targeting HIPK2 to inhibit kidney fibrosis. The breakthrough discovery aiming to advance the treatment of renal disease was developed in collaboration with Mount […]